Cited by 1,204

The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.

Contribution of de novo fatty acid synthesis to hepatic steatosis and insulin resistance: lessons from genetically engineered mice

Open access

Postic, Catherine, Girard, Jean·2008·Journal of Clinical Investigation

Open this paper in CoChat — free account

Abstract

Nonalcoholic fatty liver disease (NAFLD) is associated with obesity, insulin resistance, and type 2 diabetes. NAFLD represents a large spectrum of diseases ranging from (i) fatty liver (hepatic steatosis); (ii) steatosis with inflammation and necrosis; and (iii) cirrhosis. Although the molecular mechanism leading to the development of hepatic steatosis in the pathogenesis of NAFLD is complex, recent animal models have shown that modulating important enzymes in fatty acid synthesis in liver may be key for the treatment of NAFLD. This review discusses recent advances in the field.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1172/jci34275

Cites

20 of 20 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease
Donnelly, K. L., Smith, C. I., Schwarzenberg, S. J., Jessurun, J., Boldt, M. D., & Parks, E. J. (2005) · Journal of Clinical Investigation · doi:10.1172/jci23621 · Cited by 3,604
A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis
Belfort, R., Harrison, S. A., Brown, K., Darland, C., Finch, J., Hardies, J., Balas, B., Gastaldelli, A., Tio, F., Pulcini, J., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa060326 · Cited by 1,827
The Mitochondrial Carnitine Palmitoyltransferase System — From Concept to Molecular Analysis
McGarry, J. D., & Brown, N. F. (1997) · European Journal of Biochemistry · doi:10.1111/j.1432-1033.1997.00001.x · Cited by 1,616
Insulin-regulated hepatic gluconeogenesis through FOXO1–PGC-1α interaction
Puigserver, P., Rhee, J., Donovan, J., Walkey, C. J., Yoon, J. C., Oriente, F., Kitamura, Y., Altomonte, J., Dong, H., Accili, D., et al. (2003) · Nature · doi:10.1038/nature01667 · Cited by 1,487
Mechanism of hepatic insulin resistance in non-alcoholic fatty liver disease
Samuel, V. T., Liu, Z.-X., Qu, X., Elder, B. D., Bilz, S., Befroy, D., Romanelli, A. J., & Shulman, G. I. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m313478200 · Cited by 1,322
Obesity-associated improvements in metabolic profile through expansion of adipose tissue
Kim, J.-Y., van de Wall, E., Laplante, M., Azzara, A., Trujillo, M. E., Hofmann, S. M., Schraw, T., Durand, J. L., Li, H., Li, G., et al. (2007) · Journal of Clinical Investigation · doi:10.1172/jci31021 · Cited by 1,310
Continuous fatty acid oxidation and reduced fat storage in mice lacking acetyl-CoA carboxylase 2
Abu-Elheiga, L., Matzuk, M. M., Abo-Hashema, K. A. H., & Wakil, S. J. (2001) · Science · doi:10.1126/science.1056843 · Cited by 903
A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis
Promrat, K., Lutchman, G., Uwaifo, G. I., Freedman, R. J., Soza, A., Heller, T., Doo, E., Ghany, M., Premkumar, A., Park, Y., et al. (2004) · Hepatology · doi:10.1002/hep.20012 · Cited by 726
Diminished hepatic response to fasting/refeeding and liver X receptor agonists in mice with selective deficiency of sterol regulatory element-binding protein-1c
Liang, G., Yang, J., Horton, J. D., Hammer, R. E., Goldstein, J. L., & Brown, M. S. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m111421200 · Cited by 669
Regulation of Plasma Triglycerides in Insulin Resistance and Diabetes
Ginsberg, H. N., Zhang, Y.-L., & Hernandez-Ono, A. (2005) · Archives of Medical Research · doi:10.1016/j.arcmed.2005.01.005 · Cited by 531

Show all 20 references

The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD)
Buzzetti, E., Pinzani, M., & Tsochatzis, E. A. (2016) · Metabolism · doi:10.1016/j.metabol.2015.12.012 · Cited by 3,119
Evolution of inflammation in nonalcoholic fatty liver disease: The multiple parallel hits hypothesis
Tilg, H., & Moschen, A. R. (2010) · Hepatology · doi:10.1002/hep.24001 · Cited by 2,548
Molecular mechanisms of hepatic lipid accumulation in non-alcoholic fatty liver disease
Ipsen, D. H., Lykkesfeldt, J., & Tveden-Nyborg, P. (2018) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-018-2860-6 · Cited by 1,471
Glucose transporters in the 21st Century
Thorens, B., & Mueckler, M. (2010) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00712.2009 · Cited by 1,013
The randle cycle revisited: a new head for an old hat.
Hue, L., & Taegtmeyer, H. (2009) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00093.2009 · Cited by 743
GRP78 expression inhibits insulin and ER stress–induced SREBP-1c activation and reduces hepatic steatosis in mice
Kammoun, H. L., Chabanon, H., Hainault, I., Luquet, S., Magnan, C., Koike, T., Ferré, P., & Foufelle, F. (2009) · Journal of Clinical Investigation · doi:10.1172/jci37007 · Cited by 732
Role of Dietary Fructose and Hepatic De Novo Lipogenesis in Fatty Liver Disease
Softic, S., Cohen, D. E., & Kahn, C. R. (2016) · Digestive Diseases and Sciences · doi:10.1007/s10620-016-4054-0 · Cited by 709
The gut microbiota modulates host energy and lipid metabolism in mice
Velagapudi, V. R., Hezaveh, R., Reigstad, C. S., Gopalacharyulu, P., Yetukuri, L., Islam, S., Felin, J., Perkins, R., Borén, J., Orešič, M., et al. (2010) · Journal of Lipid Research · doi:10.1194/jlr.m002774 · Cited by 589
Untitled work
(2010) · doi:10.1016/j.cmet.2010.06.009 · Cited by 512
mTOR Signaling in Disease
Dazert, E., & Hall, M. N. (2011) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2011.09.003 · Cited by 460
From NASH to diabetes and from diabetes to NASH: Mechanisms and treatment options
Gastaldelli, A., & Cusi, K. (2019) · JHEP Reports · doi:10.1016/j.jhepr.2019.07.002 · Cited by 455
New insights into the pathophysiology of dyslipidemia in type 2 diabetes
Taskinen, M.-R., & Borén, J. (2015) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2015.01.039 · Cited by 440
Maternal High-Fat Feeding Primes Steatohepatitis in Adult Mice Offspring, Involving Mitochondrial Dysfunction and Altered Lipogenesis Gene Expression
Bruce, K. D., Cagampang, F. R., Argenton, M., Zhang, J., Ethirajan, P. L., Burdge, G. C., Bateman, A. C., Clough, G. F., Poston, L., Hanson, M. A., et al. (2009) · Hepatology · doi:10.1002/hep.23205 · Cited by 449
Increased very low density lipoprotein (VLDL) secretion, hepatic steatosis, and insulin resistance
Choi, S. H., & Ginsberg, H. N. (2011) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2011.04.007 · Cited by 418
The lipogenic transcription factor ChREBP dissociates hepatic steatosis from insulin resistance in mice and humans
Benhamed, F., Denechaud, P.-D., Lemoine, M., Robichon, C., Moldes, M., Bertrand-Michel, J., Ratziu, V., Serfaty, L., Housset, C., Capeau, J., et al. (2012) · Journal of Clinical Investigation · doi:10.1172/jci41636 · Cited by 408
Self-citation
Use of rodents as models of human diseases
Vandamme, T. (2014) · Journal of Pharmacy And Bioallied Sciences · doi:10.4103/0975-7406.124301 · Cited by 389
Mechanisms of Glucocorticoid-Induced Insulin Resistance
Geer, E. B., Islam, J., & Buettner, C. (2014) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2013.10.005 · Cited by 392
Enhanced free cholesterol, SREBP-2 and StAR expression in human NASH
Caballero, F., Fernández, A., De Lacy, A. M., Fernández-Checa, J. C., Caballería, J., & García-Ruiz, C. (2009) · Journal of Hepatology · doi:10.1016/j.jhep.2008.12.016 · Cited by 368
Trans-Palmitoleic Acid, Metabolic Risk Factors, and New-Onset Diabetes in U.S. Adults: A Cohort Study
Mozaffarian, D., Cao, H., King, I. B., Lemaitre, R. N., Song, X., Siscovick, D. S., & Hotamisligil, G. S. (2010) · Annals of Internal Medicine · doi:10.7326/0003-4819-153-12-201012210-00005 · Cited by 363
A murine model for non-alcoholic steatohepatitis showing evidence of association between diabetes and hepatocellular carcinoma
Fujii, M., Shibazaki, Y., Wakamatsu, K., Honda, Y., Kawauchi, Y., Suzuki, K., Arumugam, S., Watanabe, K., Ichida, T., Asakura, H., et al. (2013) · Medical Molecular Morphology · doi:10.1007/s00795-013-0016-1 · Cited by 355
Hepatic Hdac3 promotes gluconeogenesis by repressing lipid synthesis and sequestration
Sun, Z., Miller, R. A., Patel, R. T., Chen, J., Dhir, R., Wang, H., Zhang, D., Graham, M. J., Unterman, T. G., Shulman, G. I., et al. (2012) · Nature Medicine · doi:10.1038/nm.2744 · Cited by 335
Foxo1 integrates insulin signaling with mitochondrial function in the liver
Cheng, Z., Guo, S., Copps, K., Dong, X., Kollipara, R., Rodgers, J. T., Depinho, R. A., Puigserver, P., & White, M. F. (2009) · Nature Medicine · doi:10.1038/nm.2049 · Cited by 321
Glucagon-like peptide-1 reduces hepatic lipogenesis via activation of AMP-activated protein kinase
Ben-Shlomo, S., Zvibel, I., Shnell, M., Shlomai, A., Chepurko, E., Halpern, Z., Barzilai, N., Oren, R., & Fishman, S. (2011) · Journal of Hepatology · doi:10.1016/j.jhep.2010.09.032 · Cited by 328
Omega-3 Fatty Acids, Hepatic Lipid Metabolism, and Nonalcoholic Fatty Liver Disease
Scorletti, E., & Byrne, C. D. (2013) · Annual Review of Nutrition · doi:10.1146/annurev-nutr-071812-161230 · Cited by 326
Thyroid hormone stimulates hepatic lipid catabolism via activation of autophagy
Sinha, R. A., You, S.-H., Zhou, J., Siddique, M. M., Bay, B.-H., Zhu, X., Privalsky, M. L., Cheng, S.-Y., Stevens, R. D., Summers, S. A., et al. (2012) · Journal of Clinical Investigation · doi:10.1172/jci60580 · Cited by 303
Hepatic Selective Insulin Resistance at the Intersection of Insulin Signaling and Metabolic Dysfunction-Associated Steatotic Liver Disease
Bo, T., Gao, L., Yao, Z., Shao, S., Wang, X., Proud, C. G., & Zhao, J. (2024) · Cell Metabolism · doi:10.1016/j.cmet.2024.04.006 · Cited by 293
Measuring and estimating insulin resistance in clinical and research settings
Gastaldelli, A. (2022) · Obesity · doi:10.1002/oby.23503 · Cited by 244
Acetyl-CoA carboxylase inhibition disrupts metabolic reprogramming during hepatic stellate cell activation
Bates, J., Vijayakumar, A., Ghoshal, S., Marchand, B., Yi, S., Kornyeyev, D., Zagorska, A., Hollenback, D., Walker, K., Liu, K., et al. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2020.04.037 · Cited by 230
Targeting fatty acid metabolism to improve glucose metabolism
Stinkens, R., Goossens, G. H., Jocken, J. W. E., & Blaak, E. E. (2015) · Obesity Reviews · doi:10.1111/obr.12298 · Cited by 183
Bariatric surgery in patients with non-alcoholic fatty liver disease - from pathophysiology to clinical effects
Laursen, T. L., Hagemann, C. A., Wei, C., Kazankov, K., Thomsen, K. L., Knop, F. K., & Grønbæk, H. (2019) · World Journal of Hepatology · doi:10.4254/wjh.v11.i2.138 · Cited by 176
Pathophysiology of NASH: perspectives for a targeted treatment
Marra, F., & Lotersztajn, S. (2013) · Current Pharmaceutical Design · doi:10.2174/13816128113199990344 · Cited by 163
Liver-specific expression of transcriptionally active SREBP-1c is associated with fatty liver and increased visceral fat mass
Knebel, B., Haas, J., Hartwig, S., Jacob, S., Köllmer, C., Nitzgen, U., Muller–Wieland, D., & Kotzka, J. (2012) · PLoS ONE · doi:10.1371/journal.pone.0031812 · Cited by 162
“Liver-specific overespression of human SREBP-1c influences parameters of systemic insulin sensitivity Excess intracellular hepatic lipid accumulation can affect insulin sensitivity in human studies and mouse models [2,3,21].”
Background
Time-Resolved and Tissue-Specific Systems Analysis of the Pathogenesis of Insulin Resistance
Kleemann, R., van Erk, M., Verschuren, L., van den Hoek, A. M., Koek, M., Wielinga, P. Y., Jie, A., Pellis, L., Bobeldijk-Pastorova, I., Kelder, T., et al. (2010) · PLoS ONE · doi:10.1371/journal.pone.0008817 · Cited by 146
Differential hepatic distribution of insulin receptor substrates causes selective insulin resistance in diabetes and obesity
Kubota, N., Kubota, T., Kajiwara, E., Iwamura, T., Kumagai, H., Watanabe, T., Inoue, M., Takamoto, I., Sasako, T., Kumagai, K., et al. (2016) · Nature Communications · doi:10.1038/ncomms12977 · Cited by 143
How Inflammation Impinges on NAFLD: A Role for Kupffer Cells
Duarte, N., Coelho, I. C., Patarrão, R. S., Almeida, J. I., Penha-Gonçalves, C., & Macedo, M. P. (2015) · BioMed Research International · doi:10.1155/2015/984578 · Cited by 120
“Moreover, this carbohydrate was reported to stimulate hepatic DNL through increasing the expression of two transcription factors, sterol regulatory elementbinding protein-1c (SREBP-1c) and carbohydrate-responsive element-binding protein (ChREBP), that regulate the activity of lipogenic enzymes [34].”
Mangiferin decreases plasma free fatty acids through promoting its catabolism in liver by activation of AMPK
Niu, Y., Li, S., Na, L., Feng, R., Liu, L., Li, Y., & Sun, C. (2012) · PLoS ONE · doi:10.1371/journal.pone.0030782 · Cited by 116
Hepatic Oxidative Stress Promotes Insulin-STAT-5 Signaling and Obesity by Inactivating Protein Tyrosine Phosphatase N2
Gurzov, E. N., Tran, M., Fernandez-Rojo, M. A., Merry, T. L., Zhang, X., Xu, Y., Fukushima, A., Waters, M. J., Watt, M. J., Andrikopoulos, S., et al. (2014) · Cell Metabolism · doi:10.1016/j.cmet.2014.05.011 · Cited by 111
Osteopontin deficiency protects against obesity-induced hepatic steatosis and attenuates glucose production in mice
Kiefer, F. W., Neschen, S., Pfau, B., Legerer, B., Neuhofer, A., Kahle, M., Hrabé de Angelis, M., Schlederer, M., Mair, M., Kenner, L., et al. (2011) · Diabetologia · doi:10.1007/s00125-011-2170-0 · Cited by 104
PNPLA3 is a triglyceride lipase that mobilizes polyunsaturated fatty acids to facilitate hepatic secretion of large-sized very low-density lipoprotein
Johnson, S. M., Bao, H., McMahon, C. E., Chen, Y., Burr, S. D., Anderson, A. M., Madeyski-Bengtson, K., Lindén, D., Han, X., & Liu, J. (2024) · Nature Communications · doi:10.1038/s41467-024-49224-x · Cited by 100
Autophagy in chronic liver diseases: the two faces of Janus
Gual, P., Gilgenkrantz, H., & Lotersztajn, S. (2017) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00295.2016 · Cited by 91
The role of hepassocin in the development of non-alcoholic fatty liver disease
Wu, H.-T., Lu, F.-H., Ou, H.-Y., Su, Y.-C., Hung, H.-C., Wu, J.-S., Yang, Y.-C., Wu, C.-L., & Chang, C.-J. (2013) · Journal of Hepatology · doi:10.1016/j.jhep.2013.06.004 · Cited by 92
Enhancing liver mitochondrial fatty acid oxidation capacity in obese mice improves insulin sensitivity independently of hepatic steatosis
Monsénégo, J., Mansouri, A., Akkaoui, M., Lenoir, V., Esnous, C., Fauveau, V., Tavernier, V., Girard, J., & Prip-Buus, C. (2012) · Journal of Hepatology · doi:10.1016/j.jhep.2011.10.008 · Cited by 91
Self-citation
Circadian- and UPR-dependent control of CPEB4 mediates a translational response to counteract hepatic steatosis under ER stress
Maillo, C., Martín, J., Sebastián, D., Hernández-Alvarez, M., García-Rocha, M., Reina, O., Zorzano, A., Fernandez, M., & Méndez, R. (2017) · Nature Cell Biology · doi:10.1038/ncb3461 · Cited by 82
Increased prevalence of non-alcoholic fatty liver disease in European women with a history of gestational diabetes
Forbes, S., Taylor-Robinson, S. D., Patel, N., Allan, P., Walker, B. R., & Johnston, D. G. (2011) · Diabetologia · doi:10.1007/s00125-010-2009-0 · Cited by 81
Interaction between sarcopenia and nonalcoholic fatty liver disease
Joo, S. K., & Kim, W. (2023) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2022.0358 · Cited by 78
Sex Hormone-Binding Globulin Reduction in Metabolic Disorders May Play a Role in NAFLD Development
(2017) · EndocrinologyJN · doi:10.1210/en.2016-1668 · Cited by 71
Weight loss amelioration of non-alcoholic steatohepatitis linked to shifts in hepatic ceramide expression and serum ceramide levels
Promrat, K., Longato, L., Wands, J. R., & de la Monte, S. M. (2011) · Hepatology Research · doi:10.1111/j.1872-034x.2011.00815.x · Cited by 66
Hypolipidemic Activity of Peony Seed Oil Rich in α-Linolenic, is Mediated Through Inhibition of Lipogenesis and Upregulation of Fatty Acid β-Oxidation
Su, J., Ma, C., Liu, C., Gao, C., Nie, R., & Wang, H. (2016) · Journal of Food Science · doi:10.1111/1750-3841.13252 · Cited by 62
(Pro)renin Receptor Inhibition Reprograms Hepatic Lipid Metabolism and Protects Mice From Diet-Induced Obesity and Hepatosteatosis
Ren, L., Sun, Y., Lu, H., Ye, D., Han, L., Wang, N., Daugherty, A., Li, F., Wang, M., Su, F., et al. (2018) · Circulation Research · doi:10.1161/circresaha.117.312422 · Cited by 59
Free fatty acids differentially downregulate chemokines in liver sinusoidal endothelial cells: insights into non-alcoholic fatty liver disease
McMahan, R. H., Porsche, C. E., Edwards, M. G., & Rosen, H. R. (2016) · PLOS ONE · doi:10.1371/journal.pone.0159217 · Cited by 55
SARM1 deletion restrains NAFLD induced by high fat diet (HFD) through reducing inflammation, oxidative stress and lipid accumulation
Pan, Z.-G., & An, X.-S. (2018) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2018.02.115 · Cited by 50
Proton pump inhibitors suppress DNA damage repair and sensitize treatment resistance in breast cancer by targeting fatty acid synthase
Wang, C. J., Li, D., Danielson, J. A., Zhang, E. H., Dong, Z., Miller, K. D., Li, L., Zhang, J.-T., & Liu, J.-Y. (2021) · Cancer Letters · doi:10.1016/j.canlet.2021.03.026 · Cited by 51
Mangiferin treatment inhibits hepatic expression of acyl-coenzyme A: Diacylglycerol acyltransferase-2 in fructose-fed spontaneously hypertensive rats: A link to amelioration of fatty liver
Xing, X., Li, D., Chen, D., Zhou, L., Chonan, R., Yamahara, J., Wang, J., & Li, Y. (2014) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2014.08.001 · Cited by 46
The interplay between nonalcoholic fatty liver disease and atherosclerotic cardiovascular disease
Finney, A. C., Das, S., Kumar, D., McKinney, M. P., Cai, B., Yurdagul, A., & Rom, O. (2023) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2023.1116861 · Cited by 40
Exendin-4 Inhibits Hepatic Lipogenesis by Increasing β-Catenin Signaling
Seo, M. H., Lee, J., Hong, S.-W., Rhee, E.-J., Park, S. E., Park, C. Y., Oh, K. W., Park, S. W., & Lee, W.-Y. (2016) · PLOS ONE · doi:10.1371/journal.pone.0166913 · Cited by 37
Integrin-Linked Kinase Is Necessary for the Development of Diet-Induced Hepatic Insulin Resistance
Williams, A. S., Trefts, E., Lantier, L., Grueter, C. A., Bracy, D. P., James, F. D., Pozzi, A., Zent, R., & Wasserman, D. H. (2017) · Diabetes · doi:10.2337/db16-0484 · Cited by 35
Ketogenesis supports hepatic polyunsaturated fatty acid homeostasis via fatty acid elongation
Queathem, E. D., Moazzami, Z., Stagg, D. B., Nelson, A. B., Fulghum, K., Hayir, A., Seay, A., Gillingham, J. R., d’Avignon, D. A., Han, X., et al. (2025) · Science Advances · doi:10.1126/sciadv.ads0535 · Cited by 30
The new therapeutic frontier--nuclear receptors and the liver
Karpen, S. J., & Trauner, M. (2010) · Journal of Hepatology · doi:10.1016/j.jhep.2009.12.002 · Cited by 29
FDG PET/CT of the non-malignant liver in an increasingly obese world population
Keramida, G., & Peters, A. M. (2020) · Clinical Physiology and Functional Imaging · doi:10.1111/cpf.12651 · Cited by 25
Hepatic miR-192-3p reactivation alleviates steatosis by targeting glucocorticoid receptor
Wang, Z., Miu, K.-K., Zhang, X., Wan, A. T.-Y., Lu, G., Cheung, H.-H., Lee, H.-M., Kong, A. P.-S., Chan, J. C.-N., & Chan, W.-Y. (2020) · JHEP Reports · doi:10.1016/j.jhepr.2020.100179 · Cited by 22
KSRP is critical in governing hepatic lipid metabolism through controlling Per2 expression
Chou, C.-F., Zhu, X., Lin, Y.-Y., Gamble, K. L., Garvey, W. T., & Chen, C.-Y. (2015) · Journal of Lipid Research · doi:10.1194/jlr.m050724 · Cited by 20
Tlr4-mutant mice are resistant to acute alcohol-induced sterol-regulatory element binding protein activation and hepatic lipid accumulation
Zhang, Z.-H., Liu, X.-Q., Zhang, C., He, W., Wang, H., Chen, Y.-H., Liu, X.-J., Chen, X., & Xu, D.-X. (2016) · Scientific Reports · doi:10.1038/srep33513 · Cited by 18
The effect of early-life stress and chronic high-sucrose diet on metabolic outcomes in female rats
Maniam, J., Antoniadis, C. P., & Morris, M. J. (2015) · Stress · doi:10.3109/10253890.2015.1079617 · Cited by 13

Authors: Postic, C., & Girard, J.
Venue: Journal of Clinical Investigation
Publisher: American Society for Clinical Investigation
Published: 2008-03-03
Volume: 118
Issue: 3
Pages: 829-838
ISSN: 0021-9738 (ISSN-L)
DOI: 10.1172/jci34275
OpenAlex: W1969734540
Cited by: 1,204
References: 20
FWCI: 37.23
Type: journal article
Language: en
Open access: bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.

Contribution of de novo fatty acid synthesis to hepatic steatosis and insulin resistance: lessons from genetically engineered mice

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Self-check

Citations

Cites

Cited by

Metadata

Record

About these checks

Data sources